Insights

Clinical-stage focus Cyteir Therapeutics is a clinical-stage oncology company with an investigational asset CYT-0851 and ongoing Phase 1/2 trials, presenting opportunities to engage in partnerships around late-stage clinical development support, trial services, and companion diagnostic discussions.

Leadership growth Recent leadership appointments (CFO and General Counsel) indicate a strengthening corporate function and potential need for financial operations, corporate services, and external/independent advisor collaborations suitable for outreach around investor relations, treasury management, and governance services.

Strategic partnerships Cyteir focuses on synthetically lethal cancer therapies, suggesting interest in collaborations with CROs, translational researchers, and technology vendors that can support clinical trial execution, data management, and regulatory affairs.

Financial position With funding of around $157M and modest revenue, there may be windows for cost optimization consulting, grant/funding strategy support, and strategic partnerships to extend runway or scale translational programs.

Market positioning Being a small, pre-commercial biotech with notable board and leadership changes and a Nasdaq listing positions Cyteir as a potential customer for advisory, market access planning, and therapeutics due diligence services when evaluating external collaborations.

Similar companies to Cyteir Therapeutics

Cyteir Therapeutics Tech Stack

Cyteir Therapeutics uses 8 technology products and services including Amazon Web Services, WordPress, NetSuite, and more. Explore Cyteir Therapeutics's tech stack below.

Media & News

Cyteir Therapeutics's Email Address Formats

Cyteir Therapeutics uses at least 2 email formats:
Cyteir Therapeutics Email FormatsExamplePercentage
First.Last@cyteir.comJohn.Doe@cyteir.com
92%
FirstLast@cyteir.comJohnDoe@cyteir.com
8%

Frequently Asked Questions

What is Cyteir Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Cyteir Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cyteir Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Cyteir Therapeutics is a publicly traded company; the company's stock symbol is CYTT.

What is Cyteir Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Cyteir Therapeutics's official website is cyteir.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Cyteir Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Cyteir Therapeutics's annual revenue is estimated to be <$1M.

What is Cyteir Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Cyteir Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 5417 - Scientific Research and Development Services.

How many employees does Cyteir Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Cyteir Therapeutics has approximately 1 employees across 1 continents, including North America. Key team members include Vp Clinical Research And Development: J. E., Founder Cyteir Therapeutics & Trc Advisory: T. R. and Svp Chemistry: J. L. Explore Cyteir Therapeutics's employee directory with LeadIQ.

What industry does Cyteir Therapeutics belong to?

Minus sign iconPlus sign icon
Cyteir Therapeutics operates in the Research Services industry.

What technology does Cyteir Therapeutics use?

Minus sign iconPlus sign icon
Cyteir Therapeutics's tech stack includes Amazon Web Services, WordPress, NetSuite, Shopify, ADP, WP Engine, Smartsheet and Sitelinks Search Box.

What is Cyteir Therapeutics's email format?

Minus sign iconPlus sign icon
Cyteir Therapeutics's email format typically follows the pattern of First.Last@cyteir.com. Find more Cyteir Therapeutics email formats with LeadIQ.

How much funding has Cyteir Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Cyteir Therapeutics has raised $157M in funding. The last funding round occurred on Feb 11, 2021 for $80M.

When was Cyteir Therapeutics founded?

Minus sign iconPlus sign icon
Cyteir Therapeutics was founded in 2012.
Cyteir Therapeutics logo

Cyteir Therapeutics

Research ServicesMassachusetts, United States0-1 Employees

Cyteir Therapeutics is a clinical-stage company in the research services sector, based in Lexington, Massachusetts. Its work centers on discovering and developing cancer therapies, including CYT-0851, an oral investigational agent that inhibits monocarboxylate transporters. CYT-0851 was being studied in combination with capecitabine and gemcitabine in a Phase 1/2 trial for patients with advanced ovarian cancer.

Beyond its lead program, Cyteir has pursued a broader focus on synthetically lethal cancer therapies. Recent leadership changes include the promotion of David Gaiero to Chief Financial Officer in February 2023.

Section iconCompany Overview

Phone number
Website
cyteir.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
CYTT
NAICS Code
5417 - Scientific Research and Development Services
Founded
2012
Employees
0-1

Section iconFunding & Financials

  • $157M

    Cyteir Therapeutics has raised a total of $157M of funding over 5 rounds. Their latest funding round was raised on Feb 11, 2021 in the amount of $80M as a Series C.

  • <$1M

    Cyteir Therapeutics's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.